| Title： | Expert Consensus on long-term medication management for solid organ transplant recipients |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Pharmacists, doctors and other relevant professional and technical personnel engaged in organ transplantation in medical institutions |
| Evidence classification method： | Not applicable |
| Development unit： | Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association; Chinese Society of Organ Transplantation |
| Registration time: | 2023-06-07 |
| Registration number： | PREPARE-2023CN384 |
| Purpose of the guideline: | The consensus mainly focuses on pharmaceutical management of immunosuppressive application after organ transplantation, drug management of infection prevention and treatment, metabolic disease complications, tumor, and comprehensive management of quality of life. The aim of the consensus is to improve long-term follow-up and management level after transplantation, promote standardization and homogenization of pharmaceutical care and practice after transplantation, and improve the quality of life and long-term survival of transplant recipients. |
